Description
Buy ALPESIB 150 MG (Alpelisib) Online
ALPESIB 150 MG is a targeted anti-cancer medication containing Alpelisib 150 mg, a selective phosphoinositide 3-kinase (PI3K) inhibitor. It is primarily prescribed for patients with HR-positive (Hormone Receptor-Positive), HER2-negative advanced or metastatic breast cancer whose tumors carry a PIK3CA mutation.
Unlike conventional chemotherapy, ALPESIB 150 MG specifically targets cancer-driving genetic mutations within the PI3K pathway. This precision-based approach helps slow tumor growth while improving the effectiveness of hormone therapy, making it an important treatment option for eligible breast cancer patients.
ALPESIB 150 MG is commonly used in combination with Fulvestrant after disease progression on endocrine therapy.
What Is ALPESIB 150 MG?
ALPESIB 150 MG contains Alpelisib, an oral targeted therapy designed to inhibit the PI3K-alpha enzyme, which plays a critical role in cancer cell growth and survival.
The PI3K signaling pathway regulates several essential cellular functions, including:
- Cell growth
- Cell division
- Cell survival
- Glucose metabolism
- Tumor development
In many patients with advanced breast cancer, mutations in the PIK3CA gene cause this pathway to become overactive. As a result, cancer cells continue to multiply and may become resistant to hormonal treatments.
By selectively blocking PI3K-alpha activity, ALPESIB 150 MG helps reduce tumor growth and improve treatment response.
Product Information
| Product Name | ALPESIB 150 MG |
|---|---|
| Generic Name | Alpelisib |
| Strength | 150 mg |
| Drug Class | PI3K Inhibitor |
| Dosage Form | Film-Coated Tablet |
| Administration Route | Oral |
| Indication | HR-Positive, HER2-Negative Advanced or Metastatic Breast Cancer |
| Prescription Required | Yes |
| Common Combination Therapy | Fulvestrant |
Uses of ALPESIB 150 MG
Treatment of Advanced Breast Cancer
ALPESIB 150 MG is indicated for the treatment of:
- Hormone receptor-positive (HR-positive) breast cancer
- HER2-negative breast cancer
- Advanced breast cancer
- Metastatic breast cancer
It is commonly prescribed for patients whose disease has progressed following previous endocrine therapy.
Patients with PIK3CA Mutations
This medication is specifically intended for patients whose tumors test positive for a PIK3CA mutation.
PIK3CA mutations are among the most common genetic alterations found in HR-positive breast cancer and are associated with:
- Faster tumor progression
- Resistance to hormonal therapies
- Poorer treatment outcomes
Targeting this mutation allows ALPESIB 150 to deliver a more personalized treatment approach.
Combination Therapy with Fulvestrant
ALPESIB 150 MG is often administered together with Fulvestrant, an estrogen receptor antagonist.
This combination works by:
- Blocking hormone-driven cancer growth
- Targeting cancer-promoting molecular pathways
- Delaying disease progression
- Improving progression-free survival
How ALPESIB 150 MG Works
Alpelisib selectively inhibits the PI3K-alpha enzyme, a critical component of the PI3K signaling pathway.
When the PI3K pathway becomes abnormally activated due to PIK3CA mutations, cancer cells receive continuous signals that promote:
- Rapid growth
- Cell survival
- Tumor spread
- Resistance to endocrine therapy
ALPESIB 150 MG blocks these signals and helps:
- Slow tumor growth
- Reduce cancer cell survival
- Improve response to hormone therapy
- Delay disease progression
Because it specifically targets cancer-related mutations, ALPESIB 150 MG offers a more focused treatment strategy than traditional chemotherapy.
Recommended Dosage
Standard Adult Dose
The usual recommended dose is:
300 mg orally once daily
This is typically administered as:
Two ALPESIB 150 MG tablets taken together once daily
Always follow your oncologist’s instructions regarding dosage adjustments.
How to Take ALPESIB 150 MG
For best results:
- Take the tablets with food.
- Take the medication at the same time each day.
- Swallow tablets whole with water.
- Do not crush, split, chew, or break the tablets.
- Do not use damaged tablets.
Taking ALPESIB 150 MG with food helps improve absorption and maintain consistent drug levels.
Missed Dose Instructions
If you miss a dose:
- Take it within 9 hours of the scheduled time if possible.
- If more than 9 hours have passed, skip the missed dose.
- Resume your normal dosing schedule the following day.
Do not take two doses at the same time to make up for a missed dose.
Benefits of ALPESIB 150
Precision Targeted Therapy
Designed specifically for tumors carrying PIK3CA mutations.
Non-Chemotherapy Treatment
Targets cancer-driving pathways rather than attacking all rapidly dividing cells.
Improved Treatment Outcomes
May help extend progression-free survival when combined with Fulvestrant.
Convenient Oral Administration
Tablet form allows treatment at home without intravenous infusions.
Helps Overcome Hormone Resistance
Can restore sensitivity to endocrine therapy in certain patients with resistant disease.
Side Effects of ALPESIB
Like all medications, ALPESIB 150 MG may cause side effects. Some reactions require medical attention and ongoing monitoring.
Hyperglycemia (High Blood Sugar)
One of the most common side effects.
Symptoms may include:
- Excessive thirst
- Frequent urination
- Fatigue
- Blurred vision
Regular blood glucose monitoring is usually recommended.
Skin Rash
Patients may experience:
- Rash
- Redness
- Itching
- Skin irritation
Some skin reactions can become severe and require treatment.
Gastrointestinal Side Effects
Common digestive symptoms include:
- Diarrhea
- Nausea
- Vomiting
- Reduced appetite
- Weight loss
Severe diarrhea can lead to dehydration if left untreated.
Mouth Sores (Stomatitis)
Some patients develop:
- Mouth ulcers
- Oral inflammation
- Painful swallowing
Fatigue
General tiredness and weakness are commonly reported during treatment.
Important Safety Information
Blood Sugar Monitoring
Alpelisib can significantly affect glucose metabolism.
Patients with:
- Diabetes
- Prediabetes
- Obesity
- Metabolic disorders
may require closer monitoring.
Serious Skin Reactions
Seek immediate medical attention if you experience:
- Severe rash
- Skin peeling
- Blistering
- Painful skin irritation
Diarrhea and Dehydration
Persistent diarrhea can cause:
- Fluid loss
- Electrolyte imbalance
- Kidney complications
Prompt management is important.
Liver Function Monitoring
Routine blood tests may be required to monitor liver function during treatment.
Pregnancy and Breastfeeding
Pregnancy
ALPESIB 150 MG may cause harm to an unborn baby.
Women of childbearing potential should use effective contraception during treatment and for the period recommended by their healthcare provider.
Breastfeeding
Breastfeeding is generally not recommended while receiving ALPESIB 150 MG treatment.
Always discuss family planning and pregnancy concerns with your oncologist before starting therapy.
Drug Interactions
ALPESIB 150 MG may interact with other medications, including:
- Prescription drugs
- Over-the-counter medicines
- Herbal supplements
- Vitamins
- Nutritional products
Inform your healthcare provider about all medications you are currently taking before starting treatment.
Storage Instructions
Store ALPESIB 150 MG properly to maintain its effectiveness:
- Store below 25°C (77°F)
- Keep in a cool, dry place
- Protect from moisture and direct sunlight
- Keep out of reach of children
- Do not use after the expiration date
Frequently Asked Questions
1.What is ALPESIB 150 MG used for?
Ans: ALPESIB 150 MG is used to treat HR-positive, HER2-negative advanced or metastatic breast cancer with a confirmed PIK3CA mutation.
2.Is ALPESIB 150 MG chemotherapy?
Ans: No. ALPESIB 150 MG is a targeted therapy that specifically blocks the PI3K-alpha pathway involved in cancer growth.
3.Can ALPESIB 150 MG be taken alone?
Ans: It is most commonly prescribed in combination with Fulvestrant for eligible patients.
4.How long should I take ALPESIB 150 MG?
Ans: Treatment duration varies based on your response, disease progression, and your oncologist’s recommendations.
5.What is the most common side effect of Alpelisib?
Ans: Hyperglycemia (high blood sugar) is one of the most frequently reported side effects and requires regular monitoring.
Why Choose ALPESIB 150 MG?
ALPESIB 150 MG represents an important advancement in precision oncology for patients with PIK3CA-mutated HR-positive, HER2-negative advanced breast cancer. By targeting the PI3K-alpha pathway, it addresses a key genetic driver of cancer growth and treatment resistance.
When used as part of a personalized treatment plan alongside Fulvestrant, it can help slow disease progression and provide a valuable treatment option for patients who have experienced progression after hormone therapy.
Note: ALPESIB should only be used under the supervision of a qualified oncologist. Regular monitoring, laboratory testing, and adherence to prescribed treatment schedules are essential for achieving the best possible outcomes.
